Skip to main content

Table 2 Medications given to patients within the last 24 h before testing in sample I

From: Do drug treatment variables predict cognitive performance in multidrug-treated opioid-dependent patients? A regression analysis study

 

Buprenorphine (n = 52)

Methadone (n = 52)

Group comparison p-values

Opioid agonist drug (M ± SD)

20 ± 6 mg

−

−

Buprenorphine (M ± SD)

−

113 ± 49 mg

 

Patients using any psychoactive medication, other than opioid

42 (81%)

43 (83%)

p = 1.00

Patients using any BDZ drug

37 (71%)

38 (73%)

p = 1.00

diazepam

29 (56%)

24 (46%)

p = .43

oxazepam

8 (15%)

14 (27%)

p = .15

Benzodiazepine, diazepam equivalent dose (M ± SD)

22 ± 10 mg

21 ± 10 mg

p = 0.77

The number psychoactive drugs, other than opioid or BZDa

   

(M ± SD)

1.2 ± 1.2

1.2 ± 1.2

p = .81

0, no. patients (%)

18 (35%)

19 (36%)

p = 1.00

1 no. patients (%)

19 (37%)

13 (25%)

p = .29

2 no. patients (%)

9 (17%)

13 (25%)

p = .47

3 no. patients (%)

2 (4%)

5 (10%)

p = .44

4 or more no. patients (%)

4 (7%)

2 (4%)

p = .68

Patients using psychoactive drug, other than opioid or BZD

   

Any drugb

34 (65%)

33 (63%)

p = 1.00

Anticonvulsants

6 (12%)

5 (10%)

p = 1.00

Antidepressants

22 (42%)

13 (25%)

p = .096

Antihistamines

6 (12%)

10 (19%)

p = .42

Neuroleptics

7 (13%)

9 (17%)

p = .79

Non-Benzodiazepine hypnotics

16 (31%)

19 (37%)

p = .68

Non-opioid pain killers

4 (8%)

6 (12%)

p = .74

  1. aTested with t-test or Fisher’s Exact Test.
  2. bThese included anticonvulsants (used as mood stabilizers), antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and non-opioid pain killers.